冠心舒通胶囊对冠心病介入治疗术后再狭窄抑制作用的临床研究

Clinical Study on the Inhibiting Effect of Coronary Heart Shutong Capsule on Restenosis after Percutaneous Coronary Intervention

目的:探索蒙西医结合治疗冠心病介入治疗术后再狭窄的有效途径和方法.方法:回顾分析2007-10～2009-01来我院确诊冠心病并行支架置入术治疗的患者41例,实验组和对照组均用西医综合疗法,而实验组在西医综合疗法基础上服用冠心舒通胶囊,每次3粒,每日3次,观察治疗前、治疗六个月后的主要症状、体征及心电图、血流变等指标变化.结果:实验组与对照组对比,心电图表现和胸闷、气短等临床症状两组比较无显著差异.实验组药物具有明显的降低胆固醇和低密度脂蛋白的作用.全血黏度、血浆纤维蛋白原和血浆黏度,实验组较对照组明显下降.两组药物治疗后均无再狭窄的发生,明显低于目前支架术后再狭窄发生率.结论:证实联合应用冠心舒通胶囊对PCI术后患者的预后改善作用及降低PCI术后的再狭窄率.

Objective： To investigate the effective approaches and methods of integrated mongolian-western therapy for the treatment of restenosis after percutaneous coronary intervention（PCI）. Methods： Retrospectively analysed 41 patients who diagnosed as coronary heart disease and underwent stent implantation treatment in October 2007 to January 2009. The 41 patients were divided into experimental and control groups, both groups were treated with Western combined therapy, on that basis, The experimental group were administered Coronary heart Shutong capsules, three at a time and three times a day, observing the main symptoms, signs and ECG, blood flow changes and so on before treatment and after 6 month＇ s treatment. Results： There were no significant difference on ECG, chest tightness, shortness of breath and other symptoms between the two groups, but in experimental group, drugs had significant role of reducing cholesterol and low-density lipoprotein. The whole blood viscosity, plasma fibrinogen and plasma viscosity of experimental group were much lower than control group. There was no occurrence of restenosis in both groups, which was much lower than the current stent implantation. Conclusion： The combined application of Coronary heart Shutong capsule can improve prognosis of patients and reduce the rate of restenosis after PCI.